The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases Article Swipe
Anneliene Hechtelt Jonker
,
Daniel O’Connor
,
Michela Gabaldo
,
Simon Day
,
Martin de Kort
,
Heather Stone
,
Anna M.G. Pasmooij
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.58647/rexpo.23004
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.58647/rexpo.23004
Drug repurposing is an exciting topic in the world of rare diseases, and it has often been suggested as a key approach for developing more therapies for the estimated 6000-8000 rare diseases. This strategy can be an attractive option because it often involves developing therapies in an efficient, potentially cheaper, and innovative way, building on previous knowledge and experience. Drug repurposing can be defined in several ways but in broad terms, can be considered as developing an existing drug in an indication outside the scope of the original indication, with the ultimate purpose of obtaining a new regulator-approved indication. Several tools and incentives have been developed to stimulate and ease the approach for repurposing for rare diseases. Nevertheless, the field still sees quite some challenges, such as intellectual property issues, lack of knowledge on regulatory requirements, the need for additional (re)formulation or obtaining additional safety-efficacy data that may be difficult to collect, and difficulties in commercialization due to the lack of sustainable business models. Consequently, repurposing approaches for rare diseases have, until now, not been as impactful as anticipated. We will present the work of IRDiRC’s Therapies Scientific Committee Task Force, following the previously launched Orphan Drug Development Guidebook. We set out to develop a Drug Repurposing Guidebook. This Guidebook is developed for researchers and developers involved in drug repurposing in the rare disease space, specifically academics, startups, small and medium enterprises, and patient-led groups. This Drug Repurposing Guidebook gathered and reviewed tools and created a roadmap to help deliver an efficient development program. This roadmap is integrated with a Gannt chart, highlighting the key repurposing activities for each development phase with checklists to consider the necessary steps to be implemented before starting a repurposing project. As such, this Guidebook can help researchers and developers who want to optimize a repurposing project for rare diseases. By allowing an understanding of the available tools, by asking the developer essential questions at different stages and directing them to the available resources, repurposing for rare diseases can be faster and more efficient, and more aligned with the regulatory processes.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.58647/rexpo.23004
- https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdf
- OA Status
- gold
- References
- 1
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4386687600
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4386687600Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.58647/rexpo.23004Digital Object Identifier
- Title
-
The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseasesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-09-12Full publication date if available
- Authors
-
Anneliene Hechtelt Jonker, Daniel O’Connor, Michela Gabaldo, Simon Day, Martin de Kort, Heather Stone, Anna M.G. PasmooijList of authors in order
- Landing page
-
https://doi.org/10.58647/rexpo.23004Publisher landing page
- PDF URL
-
https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdfDirect OA link when available
- Concepts
-
Repurposing, Drug repositioning, Computer science, Drug, Drug discovery, Medicine, Pharmacology, Bioinformatics, Engineering, Biology, Waste managementTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
1Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4386687600 |
|---|---|
| doi | https://doi.org/10.58647/rexpo.23004 |
| ids.doi | https://doi.org/10.58647/rexpo.23004 |
| ids.openalex | https://openalex.org/W4386687600 |
| fwci | 0.0 |
| type | article |
| title | The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11642 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.982200026512146 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1311 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Genomics and Rare Diseases |
| topics[1].id | https://openalex.org/T11287 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.967199981212616 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1306 |
| topics[1].subfield.display_name | Cancer Research |
| topics[1].display_name | Cancer Genomics and Diagnostics |
| topics[2].id | https://openalex.org/T11369 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9552000164985657 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Genetic factors in colorectal cancer |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C519536355 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7883656024932861 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q21021151 |
| concepts[0].display_name | Repurposing |
| concepts[1].id | https://openalex.org/C103637391 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7715033888816833 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q5308921 |
| concepts[1].display_name | Drug repositioning |
| concepts[2].id | https://openalex.org/C41008148 |
| concepts[2].level | 0 |
| concepts[2].score | 0.613807737827301 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[2].display_name | Computer science |
| concepts[3].id | https://openalex.org/C2780035454 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5581790804862976 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[3].display_name | Drug |
| concepts[4].id | https://openalex.org/C74187038 |
| concepts[4].level | 2 |
| concepts[4].score | 0.42400503158569336 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1418791 |
| concepts[4].display_name | Drug discovery |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.21179500222206116 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C98274493 |
| concepts[6].level | 1 |
| concepts[6].score | 0.19970080256462097 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[6].display_name | Pharmacology |
| concepts[7].id | https://openalex.org/C60644358 |
| concepts[7].level | 1 |
| concepts[7].score | 0.15699481964111328 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q128570 |
| concepts[7].display_name | Bioinformatics |
| concepts[8].id | https://openalex.org/C127413603 |
| concepts[8].level | 0 |
| concepts[8].score | 0.13797879219055176 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11023 |
| concepts[8].display_name | Engineering |
| concepts[9].id | https://openalex.org/C86803240 |
| concepts[9].level | 0 |
| concepts[9].score | 0.09715664386749268 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[9].display_name | Biology |
| concepts[10].id | https://openalex.org/C548081761 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q180388 |
| concepts[10].display_name | Waste management |
| keywords[0].id | https://openalex.org/keywords/repurposing |
| keywords[0].score | 0.7883656024932861 |
| keywords[0].display_name | Repurposing |
| keywords[1].id | https://openalex.org/keywords/drug-repositioning |
| keywords[1].score | 0.7715033888816833 |
| keywords[1].display_name | Drug repositioning |
| keywords[2].id | https://openalex.org/keywords/computer-science |
| keywords[2].score | 0.613807737827301 |
| keywords[2].display_name | Computer science |
| keywords[3].id | https://openalex.org/keywords/drug |
| keywords[3].score | 0.5581790804862976 |
| keywords[3].display_name | Drug |
| keywords[4].id | https://openalex.org/keywords/drug-discovery |
| keywords[4].score | 0.42400503158569336 |
| keywords[4].display_name | Drug discovery |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.21179500222206116 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/pharmacology |
| keywords[6].score | 0.19970080256462097 |
| keywords[6].display_name | Pharmacology |
| keywords[7].id | https://openalex.org/keywords/bioinformatics |
| keywords[7].score | 0.15699481964111328 |
| keywords[7].display_name | Bioinformatics |
| keywords[8].id | https://openalex.org/keywords/engineering |
| keywords[8].score | 0.13797879219055176 |
| keywords[8].display_name | Engineering |
| keywords[9].id | https://openalex.org/keywords/biology |
| keywords[9].score | 0.09715664386749268 |
| keywords[9].display_name | Biology |
| language | en |
| locations[0].id | doi:10.58647/rexpo.23004 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | proceedings-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases |
| locations[0].landing_page_url | https://doi.org/10.58647/rexpo.23004 |
| locations[1].id | pmh:oai:ris.utwente.nl:publications/91df4cf2-de56-4403-9ace-bd3c50131040 |
| locations[1].is_oa | True |
| locations[1].source | |
| locations[1].license | cc-by |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | |
| locations[1].license_id | https://openalex.org/licenses/cc-by |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://research.utwente.nl/en/publications/91df4cf2-de56-4403-9ace-bd3c50131040 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5059884371 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5883-7610 |
| authorships[0].author.display_name | Anneliene Hechtelt Jonker |
| authorships[0].countries | FR, NL |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210121021 |
| authorships[0].affiliations[0].raw_affiliation_string | IRDiRC, Paris, (France) |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I94624287 |
| authorships[0].affiliations[1].raw_affiliation_string | IRDiRC, Paris, (France); University of Twente, Enschede (The Netherlands) |
| authorships[0].institutions[0].id | https://openalex.org/I4210121021 |
| authorships[0].institutions[0].ror | https://ror.org/02j05s068 |
| authorships[0].institutions[0].type | other |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210121021 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Institut du Développement Durable et des Relations Internationales |
| authorships[0].institutions[1].id | https://openalex.org/I94624287 |
| authorships[0].institutions[1].ror | https://ror.org/006hf6230 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I94624287 |
| authorships[0].institutions[1].country_code | NL |
| authorships[0].institutions[1].display_name | University of Twente |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Anneliene Hechtelt Jonker |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | IRDiRC, Paris, (France), IRDiRC, Paris, (France); University of Twente, Enschede (The Netherlands) |
| authorships[1].author.id | https://openalex.org/A5060070231 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-6902-9886 |
| authorships[1].author.display_name | Daniel O’Connor |
| authorships[1].affiliations[0].raw_affiliation_string | IRDiRC, Paris, (France); MHRA, London, (United Kingdom) |
| authorships[1].affiliations[1].raw_affiliation_string | MHRA, London, (United Kingdom) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Daniel O’Connor |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | IRDiRC, Paris, (France); MHRA, London, (United Kingdom), MHRA, London, (United Kingdom) |
| authorships[2].author.id | https://openalex.org/A5060435342 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3852-9738 |
| authorships[2].author.display_name | Michela Gabaldo |
| authorships[2].affiliations[0].raw_affiliation_string | Evotec, Verona, , (Italy); IRDiRC, Paris, (France) |
| authorships[2].affiliations[1].raw_affiliation_string | Evotec, Verona, , (Italy) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Michela Gabaldo |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Evotec, Verona, , (Italy), Evotec, Verona, , (Italy); IRDiRC, Paris, (France) |
| authorships[3].author.id | https://openalex.org/A5075990586 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5672-6818 |
| authorships[3].author.display_name | Simon Day |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210091428 |
| authorships[3].affiliations[0].raw_affiliation_string | Clinical Trials Consulting & Training, North Marston, (United Kingdom) |
| authorships[3].affiliations[1].raw_affiliation_string | Clinical Trials Consulting & Training, North Marston, (United Kingdom); IRDiRC, Paris, (France) |
| authorships[3].institutions[0].id | https://openalex.org/I4210091428 |
| authorships[3].institutions[0].ror | https://ror.org/001mm6w73 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I124357947, https://openalex.org/I4210087105, https://openalex.org/I4210091428, https://openalex.org/I45129253, https://openalex.org/I90344618 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | MRC Clinical Trials Unit at UCL |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Simon Day |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Clinical Trials Consulting & Training, North Marston, (United Kingdom), Clinical Trials Consulting & Training, North Marston, (United Kingdom); IRDiRC, Paris, (France) |
| authorships[4].author.id | https://openalex.org/A5086513572 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7264-5436 |
| authorships[4].author.display_name | Martin de Kort |
| authorships[4].affiliations[0].raw_affiliation_string | EATRIS, Amsterdam (The Netherlands) |
| authorships[4].affiliations[1].raw_affiliation_string | EATRIS, Amsterdam (The Netherlands); IRDiRC, Paris, (France) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Martin de Kort |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | EATRIS, Amsterdam (The Netherlands), EATRIS, Amsterdam (The Netherlands); IRDiRC, Paris, (France) |
| authorships[5].author.id | https://openalex.org/A5053247335 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4601-5975 |
| authorships[5].author.display_name | Heather Stone |
| authorships[5].countries | US |
| authorships[5].affiliations[0].raw_affiliation_string | FDA, Washington DC (United States); IRDiRC, Paris, (France) |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I1320320070 |
| authorships[5].affiliations[1].raw_affiliation_string | FDA, Washington DC (United States) |
| authorships[5].institutions[0].id | https://openalex.org/I1320320070 |
| authorships[5].institutions[0].ror | https://ror.org/034xvzb47 |
| authorships[5].institutions[0].type | government |
| authorships[5].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | United States Food and Drug Administration |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Heather Stone |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | FDA, Washington DC (United States), FDA, Washington DC (United States); IRDiRC, Paris, (France) |
| authorships[6].author.id | https://openalex.org/A5032150304 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0641-3829 |
| authorships[6].author.display_name | Anna M.G. Pasmooij |
| authorships[6].countries | NL |
| authorships[6].affiliations[0].raw_affiliation_string | CBG, Utrecht (The Netherlands); IRDiRC, Paris, (France) |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I4210150351 |
| authorships[6].affiliations[1].raw_affiliation_string | CBG, Utrecht (The Netherlands) |
| authorships[6].institutions[0].id | https://openalex.org/I4210150351 |
| authorships[6].institutions[0].ror | https://ror.org/05mv4rb84 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210150351 |
| authorships[6].institutions[0].country_code | NL |
| authorships[6].institutions[0].display_name | Medicines Evaluation Board |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Anna Maria Gerdina Pasmooij |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | CBG, Utrecht (The Netherlands), CBG, Utrecht (The Netherlands); IRDiRC, Paris, (France) |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11642 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.982200026512146 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1311 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Genomics and Rare Diseases |
| related_works | https://openalex.org/W2899096130, https://openalex.org/W3190782215, https://openalex.org/W2902729297, https://openalex.org/W3110500039, https://openalex.org/W4255531208, https://openalex.org/W4320009247, https://openalex.org/W4206422705, https://openalex.org/W3186872001, https://openalex.org/W3174741986, https://openalex.org/W4389861022 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.58647/rexpo.23004 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | proceedings-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases |
| best_oa_location.landing_page_url | https://doi.org/10.58647/rexpo.23004 |
| primary_location.id | doi:10.58647/rexpo.23004 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://drugrepocentral.scienceopen.com/document_file/327e39ec-5a37-4292-bcfc-6e723b42eec0/ScienceOpen/10.58647_REXPO.23004_Jonker.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | proceedings-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases |
| primary_location.landing_page_url | https://doi.org/10.58647/rexpo.23004 |
| publication_date | 2023-09-12 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W4387876187 |
| referenced_works_count | 1 |
| abstract_inverted_index.a | 22, 98, 209, 250, 264, 288, 304 |
| abstract_inverted_index.<p | 0, 182 |
| abstract_inverted_index.As | 291 |
| abstract_inverted_index.By | 310 |
| abstract_inverted_index.We | 204 |
| abstract_inverted_index.an | 6, 39, 49, 79, 83, 255, 312 |
| abstract_inverted_index.as | 21, 77, 129, 178, 180 |
| abstract_inverted_index.at | 324 |
| abstract_inverted_index.be | 38, 65, 75, 151, 284, 339 |
| abstract_inverted_index.by | 318 |
| abstract_inverted_index.in | 9, 48, 67, 71, 82, 157, 222, 225 |
| abstract_inverted_index.is | 5, 215, 261 |
| abstract_inverted_index.it | 16, 43 |
| abstract_inverted_index.of | 12, 88, 96, 134, 163, 189, 314 |
| abstract_inverted_index.on | 57, 136 |
| abstract_inverted_index.or | 144 |
| abstract_inverted_index.to | 109, 153, 160, 207, 252, 278, 283, 302, 330 |
| abstract_inverted_index.and | 15, 53, 60, 104, 111, 155, 219, 234, 237, 245, 248, 298, 327, 341, 344 |
| abstract_inverted_index.but | 70 |
| abstract_inverted_index.can | 37, 64, 74, 295, 338 |
| abstract_inverted_index.due | 159 |
| abstract_inverted_index.for | 25, 29, 115, 117, 141, 170, 217, 272, 307, 335 |
| abstract_inverted_index.has | 17 |
| abstract_inverted_index.key | 23, 269 |
| abstract_inverted_index.may | 150 |
| abstract_inverted_index.new | 99 |
| abstract_inverted_index.not | 176 |
| abstract_inverted_index.out | 206 |
| abstract_inverted_index.set | 205 |
| abstract_inverted_index.the | 10, 30, 86, 89, 93, 113, 121, 139, 161, 187, 197, 226, 268, 280, 315, 320, 331, 348 |
| abstract_inverted_index.who | 300 |
| abstract_inverted_index.Drug | 62, 201, 210, 241 |
| abstract_inverted_index.Task | 194 |
| abstract_inverted_index.This | 35, 213, 240, 259 |
| abstract_inverted_index.been | 19, 107, 177 |
| abstract_inverted_index.data | 148 |
| abstract_inverted_index.drug | 81, 223 |
| abstract_inverted_index.each | 273 |
| abstract_inverted_index.ease | 112 |
| abstract_inverted_index.have | 106 |
| abstract_inverted_index.help | 253, 296 |
| abstract_inverted_index.lack | 133, 162 |
| abstract_inverted_index.more | 27, 342, 345 |
| abstract_inverted_index.need | 140 |
| abstract_inverted_index.now, | 175 |
| abstract_inverted_index.rare | 13, 33, 118, 171, 227, 308, 336 |
| abstract_inverted_index.sees | 124 |
| abstract_inverted_index.some | 126 |
| abstract_inverted_index.such | 128 |
| abstract_inverted_index.that | 149 |
| abstract_inverted_index.them | 329 |
| abstract_inverted_index.this | 293 |
| abstract_inverted_index.want | 301 |
| abstract_inverted_index.way, | 55 |
| abstract_inverted_index.ways | 69 |
| abstract_inverted_index.will | 185 |
| abstract_inverted_index.with | 92, 263, 276, 347 |
| abstract_inverted_index.work | 188 |
| abstract_inverted_index.Gannt | 265 |
| abstract_inverted_index.broad | 72 |
| abstract_inverted_index.field | 122 |
| abstract_inverted_index.have, | 173 |
| abstract_inverted_index.often | 18, 44 |
| abstract_inverted_index.phase | 275 |
| abstract_inverted_index.quite | 125 |
| abstract_inverted_index.scope | 87 |
| abstract_inverted_index.small | 233 |
| abstract_inverted_index.steps | 282 |
| abstract_inverted_index.still | 123 |
| abstract_inverted_index.such, | 292 |
| abstract_inverted_index.tools | 103, 247 |
| abstract_inverted_index.topic | 8 |
| abstract_inverted_index.until | 174 |
| abstract_inverted_index.world | 11 |
| abstract_inverted_index.Force, | 195 |
| abstract_inverted_index.Orphan | 200 |
| abstract_inverted_index.asking | 319 |
| abstract_inverted_index.before | 286 |
| abstract_inverted_index.chart, | 266 |
| abstract_inverted_index.faster | 340 |
| abstract_inverted_index.medium | 235 |
| abstract_inverted_index.option | 41 |
| abstract_inverted_index.space, | 229 |
| abstract_inverted_index.stages | 326 |
| abstract_inverted_index.terms, | 73 |
| abstract_inverted_index.tools, | 317 |
| abstract_inverted_index.Several | 102 |
| abstract_inverted_index.aligned | 346 |
| abstract_inverted_index.because | 42 |
| abstract_inverted_index.created | 249 |
| abstract_inverted_index.defined | 66 |
| abstract_inverted_index.deliver | 254 |
| abstract_inverted_index.develop | 208 |
| abstract_inverted_index.disease | 228 |
| abstract_inverted_index.groups. | 239 |
| abstract_inverted_index.issues, | 132 |
| abstract_inverted_index.models. | 166 |
| abstract_inverted_index.outside | 85 |
| abstract_inverted_index.present | 186 |
| abstract_inverted_index.project | 306 |
| abstract_inverted_index.purpose | 95 |
| abstract_inverted_index.roadmap | 251, 260 |
| abstract_inverted_index.several | 68 |
| abstract_inverted_index.allowing | 311 |
| abstract_inverted_index.approach | 24, 114 |
| abstract_inverted_index.building | 56 |
| abstract_inverted_index.business | 165 |
| abstract_inverted_index.cheaper, | 52 |
| abstract_inverted_index.collect, | 154 |
| abstract_inverted_index.consider | 279 |
| abstract_inverted_index.diseases | 172, 337 |
| abstract_inverted_index.exciting | 7 |
| abstract_inverted_index.existing | 80 |
| abstract_inverted_index.gathered | 244 |
| abstract_inverted_index.involved | 221 |
| abstract_inverted_index.involves | 45 |
| abstract_inverted_index.launched | 199 |
| abstract_inverted_index.optimize | 303 |
| abstract_inverted_index.original | 90 |
| abstract_inverted_index.previous | 58 |
| abstract_inverted_index.program. | 258 |
| abstract_inverted_index.project. | 290 |
| abstract_inverted_index.property | 131 |
| abstract_inverted_index.reviewed | 246 |
| abstract_inverted_index.starting | 287 |
| abstract_inverted_index.strategy | 36 |
| abstract_inverted_index.ultimate | 94 |
| abstract_inverted_index.6000-8000 | 32 |
| abstract_inverted_index.Committee | 193 |
| abstract_inverted_index.Guidebook | 214, 243, 294 |
| abstract_inverted_index.Therapies | 191 |
| abstract_inverted_index.available | 316, 332 |
| abstract_inverted_index.developed | 108, 216 |
| abstract_inverted_index.developer | 321 |
| abstract_inverted_index.different | 325 |
| abstract_inverted_index.difficult | 152 |
| abstract_inverted_index.directing | 328 |
| abstract_inverted_index.diseases, | 14 |
| abstract_inverted_index.diseases. | 34, 119, 309 |
| abstract_inverted_index.efficient | 256 |
| abstract_inverted_index.essential | 322 |
| abstract_inverted_index.estimated | 31 |
| abstract_inverted_index.following | 196 |
| abstract_inverted_index.impactful | 179 |
| abstract_inverted_index.knowledge | 59, 135 |
| abstract_inverted_index.necessary | 281 |
| abstract_inverted_index.obtaining | 97, 145 |
| abstract_inverted_index.questions | 323 |
| abstract_inverted_index.startups, | 232 |
| abstract_inverted_index.stimulate | 110 |
| abstract_inverted_index.suggested | 20 |
| abstract_inverted_index.therapies | 28, 47 |
| abstract_inverted_index.Guidebook. | 203, 212 |
| abstract_inverted_index.IRDiRC’s | 190 |
| abstract_inverted_index.Scientific | 192 |
| abstract_inverted_index.academics, | 231 |
| abstract_inverted_index.activities | 271 |
| abstract_inverted_index.additional | 142, 146 |
| abstract_inverted_index.approaches | 169 |
| abstract_inverted_index.attractive | 40 |
| abstract_inverted_index.checklists | 277 |
| abstract_inverted_index.considered | 76 |
| abstract_inverted_index.developers | 220, 299 |
| abstract_inverted_index.developing | 26, 46, 78 |
| abstract_inverted_index.dir="auto" | 2, 183 |
| abstract_inverted_index.efficient, | 50, 343 |
| abstract_inverted_index.incentives | 105 |
| abstract_inverted_index.indication | 84 |
| abstract_inverted_index.innovative | 54 |
| abstract_inverted_index.integrated | 262 |
| abstract_inverted_index.previously | 198 |
| abstract_inverted_index.processes. | 350 |
| abstract_inverted_index.regulatory | 137, 349 |
| abstract_inverted_index.resources, | 333 |
| abstract_inverted_index.Development | 202 |
| abstract_inverted_index.Repurposing | 211, 242 |
| abstract_inverted_index.challenges, | 127 |
| abstract_inverted_index.development | 257, 274 |
| abstract_inverted_index.experience. | 61 |
| abstract_inverted_index.implemented | 285 |
| abstract_inverted_index.indication, | 91 |
| abstract_inverted_index.indication. | 101 |
| abstract_inverted_index.patient-led | 238 |
| abstract_inverted_index.potentially | 51 |
| abstract_inverted_index.repurposing | 4, 63, 116, 168, 224, 270, 289, 305, 334 |
| abstract_inverted_index.researchers | 218, 297 |
| abstract_inverted_index.sustainable | 164 |
| abstract_inverted_index.anticipated. | 181 |
| abstract_inverted_index.difficulties | 156 |
| abstract_inverted_index.enterprises, | 236 |
| abstract_inverted_index.highlighting | 267 |
| abstract_inverted_index.intellectual | 130 |
| abstract_inverted_index.specifically | 230 |
| abstract_inverted_index.Consequently, | 167 |
| abstract_inverted_index.Nevertheless, | 120 |
| abstract_inverted_index.class="first" | 1 |
| abstract_inverted_index.requirements, | 138 |
| abstract_inverted_index.understanding | 313 |
| abstract_inverted_index.(re)formulation | 143 |
| abstract_inverted_index.safety-efficacy | 147 |
| abstract_inverted_index.commercialization | 158 |
| abstract_inverted_index.regulator-approved | 100 |
| abstract_inverted_index.id="d28564646e198">We | 184 |
| abstract_inverted_index.id="d28564646e196">Drug | 3 |
| cited_by_percentile_year | |
| countries_distinct_count | 4 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/2 |
| sustainable_development_goals[0].score | 0.6299999952316284 |
| sustainable_development_goals[0].display_name | Zero hunger |
| citation_normalized_percentile.value | 0.21907978 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |